Actively Recruiting

Phase Not Applicable
Age: 21Years - 65Years
All Genders
NCT05982769

Molecular Mechanism of Exercise in Cirrhosis

Led by The Cleveland Clinic · Updated on 2025-11-25

40

Participants Needed

1

Research Sites

218 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study aims to investigate the effects of 12 weeks of resistance or endurance exercise on patients with cirrhosis. Cirrhotic patients are prone to muscle loss (sarcopenia) and ammonia build up due to liver dysfunction. The liver which in healthy patients is able to process ammonia through ureagenesis is unable to do so in cirrhosis and ammonia is taken up either by the brain causing confusion or the skeletal muscle causing muscle loss or sarcopenia. Primary sarcopenia occurs in older individuals and can be mitigated by exercise. Secondary sarcopenia occurs in response to disease such as cancer, chronic kidney disease, multiple sclerosis, and cirrhosis of all etiologies. Resistance exercise is an excellent stimulator for muscle protein synthesis and is widely used to build muscle mass and strength but has little benefit to cardiovascular function. Endurance exercise has shown to be safe in cirrhosis however there is no set prescription for cirrhosis as there is for other disease. Endurance exercise is known to promote improved cardiovascular health, improve fatigue, and generates less ammonia build up than resistance exercise. In patients with low muscle mass it is possible that endurance exercise alone will be enough to improve muscle mass. There have been few studies on exercise and cirrhosis, those that exist have shown benefits with endurance exercise. However there are even more limited studies on resistance exercise and few to no studies on the molecular mechanisms behind exercise in cirrhosis. Study visits are described fully in the protocol and consent form. After passing a screening visit patients will undergo a maximal exercise/fitness test (pre-baseline test) and other body composition measurements. After the screening and pre-baseline visit randomization will occur (2:2:1 endurance, resistance, or SOC) arrangements will be made to have the appropriate exercise equipment given to patients. Once the exercise equipment has arrived a baseline study visit will occur. After the baseline visit the endurance exercise group will cycle 3 days per week for 60 minutes under the supervision of the study team. The resistance exercise group will perform a whole body resistance workout 2 days per week for approximately 60 minutes under the supervision of a study team member. Patients in all groups will have the fitness test repeated at weeks 4, 8 and 12. After the 12 weeks of exercise the baseline visits will be repeated and after 2 weeks patients will complete one final fitness test to examine the effects of de-training.

CONDITIONS

Official Title

Molecular Mechanism of Exercise in Cirrhosis

Who Can Participate

Age: 21Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 21 to 65 years of both genders
  • Diagnosis of cirrhosis confirmed by liver biopsy, clinical, biochemical, or imaging criteria
  • Child's score between 5 and 10
  • Model for End Stage Liver Disease (MELD) score less than 21
  • Abstinence from alcohol and recreational drugs for at least 6 months
  • No concurrent illnesses or medications affecting skeletal muscle mass, including diabetes mellitus or use of anticoagulants
  • Abdominal or liver CT scan within 1 year before enrollment for stratification
Not Eligible

You will not qualify if you...

  • Active alcohol consumption within 6 weeks before enrollment
  • Pedal edema grade 2 above the ankle
  • History of liver transplant
  • Active malignancy
  • Recent gastrointestinal bleed within 4 weeks
  • Hepatic encephalopathy within previous 6 months
  • Grade 2 or greater active esophageal varices
  • Active infection
  • Large ascites as defined by clinical imaging
  • Advanced cardiac or pulmonary disease
  • Use of corticosteroids or medications affecting muscle protein turnover or clotting
  • Clinical lab values indicating poor clotting as determined by the principal investigator
  • Inability to give informed consent or judged unlikely to perform exercise or complete study
  • End stage kidney disease with eGFR less than 15 ml/min/1.73m2 or dialysis
  • Deemed unsafe for exercise by the principal investigator due to failure to pass stress test

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Actively Recruiting

Loading map...

Research Team

S

Srinivasan Dasarathy, MD

CONTACT

A

Annette Bellar

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here